

**Supplementary Table 1.** ACR20, ACR50, and ACR70 response rates by treatment sequence in the Mexican Phase 3 study population over time (FAS, no imputation)

| <b>Month</b>          | <b>Tofacitinib<br/>5 mg BID</b> | <b>Tofacitinib<br/>10 mg BID</b> | <b>Placebo</b>               |
|-----------------------|---------------------------------|----------------------------------|------------------------------|
| <b>ACR20, % (n/N)</b> |                                 |                                  |                              |
| <b>[95% CI]</b>       |                                 |                                  |                              |
| 1                     | 56.8 (21/37)<br>[39.5, 72.9]    | 66.7 (36/54)<br>[52.5, 78.9]     | 38.5 (10/26)<br>[20.2, 59.4] |
| 3                     | 69.4 (25/36)<br>[51.9, 83.7]    | 70.4 (38/54)<br>[56.4, 82.0]     | 26.9 (7/26)<br>[11.6, 47.8]  |
| 6                     | 73.5 (25/34)<br>[55.6, 87.1]    | 81.5 (44/54)<br>[68.6, 90.8]     | 60.0 (6/10)<br>[26.2, 87.8]  |
| 9                     | 71.4 (15/21)<br>[47.8, 88.7]    | 82.5 (33/40)<br>[67.2, 92.7]     | -                            |
| 12                    | 77.8 (14/18)<br>[52.4, 93.6]    | 78.9 (30/38)<br>[62.7, 90.5]     | -                            |
| <b>ACR50, % (n/N)</b> |                                 |                                  |                              |
| <b>[95% CI]</b>       |                                 |                                  |                              |
| 1                     | 29.7 (11/37)<br>[15.9, 47.0]    | 27.8 (15/54)<br>[16.5, 41.6]     | 7.7 (2/26)<br>[1.0, 25.1]    |
| 3                     | 55.6 (20/36)<br>[38.1, 72.1]    | 50.0 (27/54)<br>[36.1, 63.9]     | 11.5 (3/26)<br>[2.5, 30.2]   |
| 6                     | 61.8 (21/34)<br>[43.6, 77.8]    | 59.3 (32/54)<br>[45.0, 72.4]     | 40.0 (4/10)<br>[12.2, 73.8]  |
| 9                     | 47.6 (10/21)<br>[25.7, 70.2]    | 62.5 (25/40)<br>[45.8, 77.3]     | -                            |
| 12                    | 61.1 (11/18)<br>[35.8, 82.7]    | 65.8 (25/38)<br>[48.7, 80.4]     | -                            |

**ACR70, % (n/N)****[95% CI]**

|    |                              |                              |                           |
|----|------------------------------|------------------------------|---------------------------|
| 1  | 13.5 (5/37)<br>[4.5, 28.8]   | 5.6 (3/54)<br>[1.2, 15.4]    | 7.7 (2/26)<br>[1.0, 25.1] |
| 3  | 25.0 (9/36)<br>[12.1, 42.2]  | 20.4 (11/54)<br>[10.6, 33.5] | 3.8 (1/26)<br>[0.1, 19.6] |
| 6  | 44.1 (15/34)<br>[27.2, 62.1] | 37.0 (20/54)<br>[24.3, 51.3] | 0.0 (0/10)<br>[0.0, 30.9] |
| 9  | 42.9 (9/21)<br>[21.8, 66.0]  | 45.0 (18/40)<br>[29.3, 61.5] | -                         |
| 12 | 38.9 (7/18)<br>[17.3, 64.3]  | 52.6 (20/38)<br>[35.8, 69.0] | -                         |

ACR, American College of Rheumatology; BID, twice daily; FAS, full analysis set; CI, confidence interval; N, number of evaluable patients at time point of interest; n, number of patients with response.

**Supplementary Table 2.** Mean (95% CI) change from baseline in DAS28-4(ESR) and mean (95% CI) change from baseline in HAQ-DI score by treatment sequence in the Mexican Phase 3 study population over time (FAS, no imputation)

| Month  | Tofacitinib<br>5 mg BID    | Tofacitinib<br>10 mg BID   | Placebo                    |
|--|----------------------------|----------------------------|----------------------------|
| <b>Change from baseline in DAS28-4(ESR), mean [95% CI] (N)</b> |                            |                            |                            |
| <b>Change from baseline in HAQ-DI, mean [95% CI] (N)</b>       |                            |                            |                            |
| 1  | -1.07 [-1.6, -0.6]<br>(10) | -1.31 [-1.8, -0.8]<br>(21) | -1.06 [-1.7, -0.4]<br>(14) |
| 3  | -2.43 [-2.9, -1.9]<br>(34) | -2.16 [-2.5, -1.8]<br>(49) | -1.03 [-1.5, -0.6]<br>(26) |
| 6  | -2.20 [-2.8, -1.6]<br>(33) | -2.54 [-2.9, -2.2]<br>(51) | -1.37 [-2.3, -0.5]<br>(10) |
| 9  | -1.96 [-2.9, -1.0]<br>(10) | -2.49 [-2.9, -2.1]<br>(21) | -                          |
| 12   | -2.39 [-3.0, -1.8]<br>(17) | -2.68 [-3.2, -2.1]<br>(36) | -                          |
| <b>Change from baseline in HAQ-DI, mean [95% CI] (N)</b>       |                            |                            |                            |
| 1  | -0.47 [-0.6, -0.3]<br>(37) | -0.61 [-0.8, -0.5]<br>(54) | -0.13 [-0.3, 0.0]<br>(26)  |
| 3  | -0.59 [-0.8, -0.4]<br>(36) | -0.78 [-1.0, -0.6]<br>(54) | -0.28 [-0.5, -0.1]<br>(26) |
| 6  | -0.64 [-0.9, -0.4]<br>(34) | -0.90 [-1.1, -0.7]<br>(54) | -0.25 [-0.7, 0.2]<br>(10)  |
| 9  | -0.78 [-1.1, -0.5]<br>(21) | -1.04 [-1.2, -0.9]<br>(40) | -                          |
| 12   | -0.74 [-1.1, -0.4]<br>(18) | -0.99 [-1.2, -0.8]<br>(38) | -                          |

BID, twice daily; CI, confidence interval; DAS28-4(ESR), Disease Activity Score (erythrocyte sedimentation rate); FAS, full analysis set; HAQ-DI, Health Assessment Questionnaire-Disability Index; N, number of evaluable patients at time point of interest.

**Supplementary Table 3.** ACR20, ACR50, and ACR70 response rates in the Mexican LTE study population over time (FAS, no imputation)

| Month | ACR20, % (n/N)<br>[95% CI]       |                                    | ACR50, % (n/N)<br>[95% CI]       |                                   | ACR70, % (n/N)<br>[95% CI]       |                                   |
|-------|----------------------------------|------------------------------------|----------------------------------|-----------------------------------|----------------------------------|-----------------------------------|
|       | Tofacitinib<br>5 mg BID          |                                    | Tofacitinib<br>10 mg BID         |                                   | Tofacitinib<br>5 mg BID          |                                   |
|       |                                  |                                    |                                  |                                   |                                  |                                   |
| 1     | 64.71<br>(55/85)<br>[53.6, 74.8] | 79.20<br>(99/125)<br>[71.0, 85.9]  | 40.00<br>(34/85)<br>[29.5, 51.2] | 52.80<br>(66/125)<br>[43.7, 61.8] | 15.29<br>(13/85)<br>[8.4, 24.7]  | 31.20<br>(39/125)<br>[23.2, 40.1] |
| 3     | 67.86<br>(57/84)<br>[56.8, 77.6] | 82.11<br>(101/123)<br>[74.2, 88.4] | 53.57<br>(45/84)<br>[42.4, 64.5] | 65.04<br>(80/123)<br>[55.9, 73.4] | 20.24<br>(17/84)<br>[12.3, 30.4] | 34.96<br>(43/123)<br>[26.6, 44.1] |
| 6     | 65.48<br>(55/84)<br>[54.3, 75.5] | 81.82<br>(99/121)<br>[73.8, 88.2]  | 46.43<br>(39/84)<br>[35.5, 57.7] | 61.16<br>(74/121)<br>[51.9, 69.9] | 29.76<br>(25/84)<br>[20.3, 40.7] | 44.63<br>(54/121)<br>[35.6, 53.9] |
| 9     | 70.37<br>(57/81)<br>[59.2, 80.0] | 76.58<br>(85/111)<br>[67.6, 84.1]  | 58.02<br>(47/81)<br>[46.5, 68.9] | 55.86<br>(62/111)<br>[46.1, 65.3] | 37.04<br>(30/81)<br>[26.6, 48.5] | 40.54<br>(45/111)<br>[31.3, 50.3] |
| 12    | 71.79<br>(56/78)<br>[60.5, 81.4] | 74.53<br>(79/106)<br>[65.1, 82.5]  | 51.28<br>(40/78)<br>[39.7, 62.8] | 59.43<br>(63/106)<br>[49.5, 68.9] | 26.92<br>(21/78)<br>[17.5, 38.2] | 46.23<br>(49/106)<br>[36.5, 56.2] |
| 15    | 81.08<br>(60/74)<br>[70.3, 89.3] | 79.80<br>(79/99)<br>[70.5, 87.2]   | 59.46<br>(44/74)<br>[47.4, 70.7] | 65.66<br>(65/99)<br>[55.4, 74.9]  | 28.38<br>(21/74)<br>[18.5, 40.1] | 45.45<br>(45/99)<br>[35.4, 55.8]  |
| 18    | 74.65<br>(53/71)<br>[62.9, 84.2] | 72.62<br>(61/84)<br>[61.8, 81.8]   | 54.93<br>(39/71)<br>[42.7, 66.8] | 60.71<br>(51/84)<br>[49.5, 71.2]  | 36.62<br>(26/71)<br>[25.5, 48.9] | 46.43<br>(39/84)<br>[35.5, 57.7]  |
| 21    | 74.29<br>(52/70)<br>[62.4, 84.0] | 71.23<br>(52/73)<br>[59.5, 81.2]   | 55.71<br>(39/70)<br>[43.3, 67.6] | 57.53<br>(42/73)<br>[45.4, 69.0]  | 32.86<br>(23/70)<br>[22.1, 45.1] | 46.58<br>(34/73)<br>[34.8, 58.6]  |
| 24    | 80.30<br>(53/66)<br>[68.7, 89.1] | 74.24<br>(49/66)<br>[62.0, 84.2]   | 59.09<br>(39/66)<br>[46.3, 71.1] | 57.58<br>(38/66)<br>[44.8, 69.7]  | 36.36<br>(24/66)<br>[24.9, 49.1] | 42.42<br>(28/66)<br>[30.3, 55.2]  |
| 27    | 77.42<br>(48/62)<br>[65.0, 87.1] | 76.47<br>(39/51)<br>[62.5, 87.2]   | 56.45<br>(35/62)<br>[43.3, 69.0] | 64.71<br>(33/51)<br>[50.1, 77.6]  | 37.10<br>(23/62)<br>[25.2, 50.3] | 47.06<br>(24/51)<br>[32.9, 61.5]  |

|    |                                  |                                  |                                  |                                  |                                  |                                  |
|----|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|
|    | 84.75<br>(50/59)<br>[73.0, 92.8] | 72.22<br>(26/36)<br>[54.8, 85.8] | 72.88<br>(43/59)<br>[59.7, 83.6] | 52.78<br>(19/36)<br>[35.5, 69.6] | 45.76<br>(27/59)<br>[32.7, 59.3] | 44.44<br>(16/36)<br>[27.9, 61.9] |
| 30 | 83.05<br>(49/59)<br>[71.0, 91.6] | 79.17<br>(19/24)<br>[57.9, 92.9] | 59.32<br>(35/59)<br>[45.8, 71.9] | 58.33<br>(14/24)<br>[36.6, 77.9] | 37.29<br>(22/59)<br>[25.0, 50.9] | 50.00<br>(12/24)<br>[29.1, 70.9] |
| 33 | 78.95<br>(45/57)<br>[66.1, 88.6] | 80.00<br>(12/15)<br>[51.9, 95.7] | 61.40<br>(35/57)<br>[47.6, 74.0] | 66.67<br>(10/15)<br>[38.4, 88.2] | 33.33<br>(19/57)<br>[21.4, 47.1] | 60.00<br>(9/15)<br>[32.3, 83.7]  |
| 36 |                                  |                                  |                                  |                                  |                                  |                                  |

ACR, American College of Rheumatology; BID, twice daily; CI, confidence interval; FAS, full analysis set; LTE, long-term extension; N, number of evaluable patients at time point of interest.

**Supplementary Table 4.** Mean (95% CI) change from baseline in DAS28-4(ESR) and mean (95% CI) change from baseline in HAQ-DI score in the Mexican LTE study population over time (FAS, no imputation)

| Month | Change from baseline in DAS28-4(ESR), mean [95% CI] (N) |                             | Change from baseline in HAQ-DI, mean [95% CI] (N) |                             |
|-------|---|-----------------------------|---|-----------------------------|
|       | Tofacitinib 5 mg BID                                    | Tofacitinib 10 mg BID       | Tofacitinib 5 mg BID                              | Tofacitinib 10 mg BID       |
|       |   |                             |   |                             |
| 1     | -1.74 [-2.0, -1.5]<br>(66)                              | -2.43 [-2.7, -2.2]<br>(124) | -0.59 [-0.7, -0.4]<br>(85)                        | -0.63 [-0.8, -0.5]<br>(124) |
| 3     | -1.92 [-2.3, -1.6]<br>(67)                              | -2.77 [-3.0, -2.5]<br>(123) | -0.58 [-0.7, -0.4]<br>(84)                        | -0.70 [-0.8, -0.6]<br>(123) |
| 6     | -1.89 [-2.2, -1.6]<br>(66)                              | -2.86 [-3.1, -2.6]<br>(121) | -0.62 [-0.8, -0.5]<br>(83)                        | -0.69 [-0.8, -0.6]<br>(121) |
| 9     | -2.19 [-2.5, -1.9]<br>(61)                              | -2.78 [-3.1, -2.5]<br>(108) | -0.65 [-0.8, -0.5]<br>(80)                        | -0.63 [-0.8, -0.5]<br>(111) |
| 12    | -2.15 [-2.5, -1.8]<br>(60)                              | -2.90 [-3.2, -2.6]<br>(103) | -0.68 [-0.8, -0.5]<br>(78)                        | -0.64 [-0.8, -0.5]<br>(104) |
| 15    | -2.25 [-2.6, -1.9]<br>(55)                              | -2.89 [-3.2, -2.6]<br>(98)  | -0.65 [-0.8, -0.5]<br>(74)                        | -0.72 [-0.9, -0.6]<br>(98)  |
| 18    | -2.21 [-2.6, -1.9]<br>(52)                              | -2.77 [-3.1, -2.4]<br>(83)  | -0.66 [-0.8, -0.5]<br>(69)                        | -0.67 [-0.9, -0.5]<br>(83)  |
| 21    | -2.07 [-2.5, -1.7]<br>(53)                              | -2.61 [-3.0, -2.3]<br>(72)  | -0.69 [-0.9, -0.5]<br>(69)                        | -0.60 [-0.8, -0.4]<br>(72)  |
| 24    | -2.25 [-2.6, -1.9]<br>(50)                              | -2.63 [-2.9, -2.3]<br>(66)  | -0.68 [-0.8, -0.5]<br>(66)                        | -0.56 [-0.7, -0.4]<br>(66)  |
| 27    | -2.33 [-2.7, -1.9]<br>(45)                              | -3.02 [-3.4, -2.7]<br>(51)  | -0.72 [-0.9, -0.6]<br>(62)                        | -0.57 [-0.8, -0.4]<br>(51)  |
| 30    | -2.56 [-3.0, -2.1]<br>(42)                              | -3.06 [-3.5, -2.7]<br>(33)  | -0.68 [-0.9, -0.5]<br>(59)                        | -0.40 [-0.7, -0.1]<br>(36)  |
| 33    | -2.43 [-2.8, -2.1]<br>(43)                              | -2.66 [-3.1, -2.2]<br>(24)  | -0.81 [-1.0, -0.6]<br>(59)                        | -0.32 [-0.6, -0.1]<br>(24)  |

|    |                            |                            |                            |                           |
|----|----------------------------|----------------------------|----------------------------|---------------------------|
| 36 | -2.49 [-2.9, -2.1]<br>(40) | -2.99 [-3.7, -2.3]<br>(15) | -0.75 [-0.9, -0.6]<br>(57) | -0.39 [-0.8, 0.0]<br>(15) |
|----|----------------------------|----------------------------|----------------------------|---------------------------|

BID, twice daily; CI, confidence interval; DAS28-4(ESR), Disease Activity Score

(erythrocyte sedimentation rate); FAS, full analysis set; HAQ-DI, Health Assessment

Questionnaire-Disability Index; LTE, long-term extension; N, number of evaluable patients at time point of interest.

**Supplementary Table 5A.** Mean change from baseline in hemoglobin and neutrophil count, and mean absolute lymphocyte count, in the Mexican Phase 3 study population over time

| <b>Month</b>  | <b>Tofacitinib<br/>5 mg BID</b> | <b>Tofacitinib<br/>10 mg BID</b> | <b>Placebo</b>       |
|---|---------------------------------|----------------------------------|----------------------|
| <b>Change from baseline in hemoglobin (g/dL), mean (SE) (N)</b>                             |                                 |                                  |                      |
|   |                                 |                                  |                      |
| 1   | 0.15 (0.12)<br>(37)             | 0.01 (0.09)<br>(54)              | -0.13 (0.20)<br>(26) |
| 3   | 0.19 (0.13)<br>(36)             | -0.25 (0.11)<br>(53)             | -0.06 (0.21)<br>(25) |
| 6   | 0.15 (0.16)<br>(41)             | -0.13 (0.12)<br>(63)             | -0.60 (0.45)<br>(10) |
| 9   | 0.67 (0.20)<br>(30)             | 0.06 (0.17)<br>(48)              |                      |
| 12  | 0.86 (0.22)<br>(28)             | 0.30 (0.17)<br>(47)              |                      |
| <b>Change from baseline neutrophil count (<math>10^3/\text{mm}^3</math>), mean (SE) (N)</b> |                                 |                                  |                      |
|   |                                 |                                  |                      |
| 1   | -0.52 (0.38)<br>(37)            | -0.84 (0.27)<br>(54)             | -0.08 (0.27)<br>(26) |
| 3   | -0.73 (0.29)<br>(36)            | -0.89 (0.26)<br>(53)             | -0.16 (0.25)<br>(25) |
| 6   | -0.87 (0.21)<br>(41)            | -1.06 (0.23)<br>(63)             | -0.01 (0.54)<br>(10) |
| 9   | -0.33 (0.34)<br>(30)            | -0.82 (0.26)<br>(48)             |                      |
| 12  | -0.17 (0.38)<br>(28)            | -0.26 (0.30)<br>(47)             |                      |
| <b>Absolute lymphocyte count (<math>10^3/\text{mm}^3</math>), mean (SE) (N)</b>             |                                 |                                  |                      |
|   |                                 |                                  |                      |
| 0   | 1.74 (0.10)<br>(37)             | 1.70 (0.10)<br>(55)              | 1.84 (0.18)<br>(27)  |

|    |                     |                     |                     |
|----|---------------------|---------------------|---------------------|
| 1  | 1.82 (0.12)<br>(37) | 1.90 (0.12)<br>(54) | 1.77 (0.17)<br>(26) |
| 3  | 1.76 (0.10)<br>(36) | 1.73 (0.10)<br>(53) | 1.96 (0.17)<br>(25) |
| 6  | 1.70 (0.11)<br>(41) | 1.71 (0.11)<br>(63) | 1.72 (0.20)<br>(10) |
| 9  | 1.83 (0.16)<br>(30) | 1.73 (0.11)<br>(48) |                     |
| 12 | 1.65 (0.13)<br>(28) | 1.37 (0.09)<br>(47) |                     |

BID, twice daily; N, number of evaluable patients at time point of interest; SE, standard error.

**Supplementary Table 5B.** Mean change from baseline in hemoglobin and neutrophil count, and mean absolute lymphocyte count, in the Mexican LTE study population over time

| Month | Change from baseline in hemoglobin (g/dL), mean (SE) (N) |                       | Change from baseline neutrophil count (10 <sup>3</sup> /mm <sup>3</sup> ), mean (SE) (N) |                       | Absolute lymphocyte count (10 <sup>3</sup> /mm <sup>3</sup> ), mean (SE) (N) |                       |
|-------|--|-----------------------|--|-----------------------|--|-----------------------|
|       | Tofacitinib 5 mg BID                                     | Tofacitinib 10 mg BID | Tofacitinib 5 mg BID   | Tofacitinib 10 mg BID | Tofacitinib 5 mg BID   | Tofacitinib 10 mg BID |
| 0     | -  | -                     | -  | -                     | 2.00 (0.08)<br>(86)  | 1.63 (0.06)<br>(126)  |
| 1     | 0.10 (0.12)<br>(85)                                      | 0.07 (0.10)<br>(124)  | -0.93 (0.20)<br>(85)   | -0.75 (0.15)<br>(124) | 2.12 (0.07)<br>(85)  | 1.68 (0.06)<br>(124)  |
| 3     | -0.09 (0.15)<br>(85)                                     | -0.02 (0.10)<br>(122) | -0.79 (0.17)<br>(84)   | -0.56 (0.18)<br>(122) | 1.98 (0.07)<br>(84)  | 1.57 (0.06)<br>(122)  |
| 12    | 0.20 (0.15)<br>(78)                                      | 0.11 (0.13)<br>(103)  | -1.31 (0.22)<br>(78)   | -0.6 (0.19)<br>(103)  | 1.62 (0.05)<br>(78)  | 1.4 (0.06)<br>(103)   |
| 18    | 0.48 (0.18)<br>(69)                                      | 0.23 (0.13)<br>(83)   | -1.17 (0.26)<br>(69)   | -0.87 (0.16)<br>(83)  | 1.51 (0.07)<br>(69)  | 1.33 (0.06)<br>(83)   |
| 24    | 0.45 (0.21)<br>(66)                                      | 0.09 (0.16)<br>(62)   | -1.52 (0.21)<br>(66)   | -0.80 (0.20)<br>(62)  | 1.45 (0.07)<br>(66)  | 1.23 (0.05)<br>(62)   |
| 30    | 0.56 (0.23)<br>(57)                                      | 0.03 (0.21)<br>(35)   | -1.17 (0.24)<br>(57)   | -1.18 (0.34)<br>(35)  | 1.53 (0.07)<br>(57)  | 1.11 (0.07)<br>(35)   |
| 36    | 0.28 (0.24)<br>(57)                                      | 0.42 (0.57)<br>(11)   | -1.37 (0.24)<br>(57)   | -0.72 (0.69)<br>(11)  | 1.40 (0.06)<br>(57)  | 1.07 (0.11)<br>(11)   |
| 42    | 0.46 (0.20)<br>(54)                                      |                       | -1.24 (0.25)<br>(54)   |                       | 1.36 (0.06)<br>(54)  |                       |
| 48    | 0.65 (0.20)<br>(52)                                      |                       | -1.04 (0.29)<br>(52)   |                       | 1.43 (0.08)<br>(52)  |                       |
| 54    | 0.66 (0.18)<br>(47)                                      |                       | -1.47 (0.24)<br>(47)   |                       | 1.34 (0.07)<br>(47)  |                       |
| 60    | 0.37 (0.22)<br>(43)                                      |                       | -1.12 (0.27)<br>(43)   |                       | 1.36 (0.09)<br>(43)  |                       |

|    |                     |                      |                     |
|----|---------------------|----------------------|---------------------|
| 66 | 0.84 (0.23)<br>(32) | -1.48 (0.31)<br>(32) | 1.29 (0.08)<br>(32) |
| 72 | 0.54 (0.34)<br>(12) | -0.91 (0.46)<br>(12) | 1.17 (0.10)<br>(12) |

BID, twice daily; LTE, long-term extension; N, number of evaluable patients at time point of interest; SE, standard error.